FFirmLensGLOBAL

Eli Lilly

LLY · NYSE · Healthcare

SEC EDGAR ↗
SEC EDGARFilings checked 15 Sept 2026, 22:20 UTCFinancials checked 15 Sept 2026, 22:20 UTC

Annual reporting period: 2025-01-01 — 2025-12-31 · USD

Annual revenue$65.18BYear over year +44.7%
Annual net income$20.64BConsolidated net income
Annual operating incomeStandard fact unavailable
Operating marginOperating income / revenue

Revenue over time

ANNUAL
2022-12-31 · 28,541,400,000 USD2022$28.54B2023-12-31 · 34,124,000,000 USD2023$34.12B2024-12-31 · 45,043,000,000 USD2024$45.04B2025-12-31 · 65,179,000,000 USD2025$65.18B

Each bar represents annual revenue for the fiscal year ending on the stated date. Compact amounts are rounded; exact values and filings are listed below.

Company & data

ELI LILLY & Co

Pharmaceutical Preparations

Market: United States
Currency: USD
CIK: 59478

A recent filing date is not a new financial period. Annual figures may remain unchanged until the next annual report, even when new current reports are filed.

How this data is calculated →

Annual financials & sources

CONSOLIDATED
FISCAL ENDREVENUENET INCOMEOPERATING INCOMESOURCE
2025-12-31$65.18B65,179,000,000 USD$20.64B20,640,000,000 USDFiling ↗
2024-12-31$45.04B45,043,000,000 USD$10.59B10,590,000,000 USDFiling ↗
2023-12-31$34.12B34,124,000,000 USD$5.24B5,240,000,000 USDFiling ↗
2022-12-31$28.54B28,541,400,000 USD$6.24B6,244,800,000 USDFiling ↗
Amounts use currency-specific compact units. Exact amounts appear below each rounded value. An em dash means unavailable, not zero.

Recent official filings

SEC EDGAR
2026-08-0510-QQuarterly report2026-08-058-KCurrent report2026-05-208-KCurrent report2026-05-078-KCurrent report2026-04-3010-QQuarterly report2026-04-308-KCurrent report2026-03-20DEF 14AProxy statement2026-02-1210-KAnnual report2026-02-048-KCurrent report2025-11-218-KCurrent report2025-10-3010-QQuarterly report2025-10-308-KCurrent report